Why is Syncom Formulations (India) Ltd falling/rising?

Recent Price Movement and Market Performance

On 05-Mar, Syncom Formulations closed at ₹11.96, down by ₹0.16 or 1.32% from the previous session. This decline extends a losing streak that has persisted for four consecutive trading days, during which the stock has fallen by 6.85%. This recent performance starkly contrasts with the benchmark Sensex, which declined by only 2.71% over the same one-week period, highlighting Syncom’s relative weakness in the current market environment.

Over longer time horizons, the stock’s underperformance is even more pronounced. Year-to-date, Syncom Formulations has declined by 16.19%, significantly lagging the Sensex’s 6.11% fall. Over the past year, the stock has dropped 24.16%, while the Sensex has gained 8.53%. These figures underscore a sustained period of underperformance relative to the broader market.

Technical Indicators Signal Continued Weakness

Technical analysis reveals that Syncom Formulations is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This positioning indicates a bearish trend and suggests that the stock is facing significant resistance levels. The consistent trading below these averages often signals investor caution and a lack of upward momentum in the near term.

Additionally, the stock’s liquidity remains adequate, with a delivery volume of 10.71 lakh shares recorded on 04-Mar. This volume represents a 28.23% increase compared to the five-day average delivery volume, indicating rising investor participation despite the falling price. However, this increased activity has not translated into price support, as selling pressure appears to be prevailing.

Comparative Returns Highlight Long-Term Challenges

While the stock has demonstrated strong long-term gains, with a 3-year return of 82.32% and an impressive 5-year return of 277.29%, these gains have not shielded it from recent volatility and declines. The contrast between the long-term outperformance and the recent underperformance suggests that investors may be reassessing the company’s near-term prospects or reacting to sector-specific challenges.

In comparison, the Sensex has delivered more modest returns over the same periods, with 33.79% over three years and 58.74% over five years, underscoring Syncom’s historical ability to outperform the market. However, the current trend indicates a phase of correction or consolidation that investors should monitor closely.

Investor Takeaway

Syncom Formulations’ recent price decline is primarily driven by its sustained underperformance relative to the Sensex and its sector, compounded by technical weakness as evidenced by trading below all major moving averages. The stock’s consecutive four-day fall and underperformance by 2.66% against its sector on the latest trading day reflect a cautious investor sentiment. Despite rising delivery volumes indicating increased trading activity, the lack of price support suggests that selling pressure remains dominant.

Investors should weigh these factors carefully, considering the stock’s long-term outperformance against its current downtrend. Monitoring upcoming market developments and sector dynamics will be crucial for assessing whether this decline represents a temporary correction or a more prolonged phase of weakness.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →